Polycythemia Vera

1. Disease Information

Definition and classification

• PV is described as a JAK2-mutated myeloproliferative neoplasm characterized by clonal erythrocytosis (tefferi2023polycythemiavera2024 pages 2-2).
• Expert clinical framing emphasizes that PV is “defined as a Philadelphia chromosome–negative MPN driven almost universally by JAK2 mutations” and that diagnostic confirmation relies on careful interpretation of red cell parameters and bone marrow morphology (silver2023polycythemiaveraaspects pages 1-3).

Common synonyms / alternative names

The evidence set supports “polycythemia vera” and “PV” as the primary naming; additional synonyms (e.g., “polycythaemia vera”) are not explicitly enumerated in the extracted texts.

Evidence provenance note (aggregated vs individual-level)

This report is derived primarily from: - Aggregated guideline/review sources (e.g., American Journal of Hematology 2024 update; national recommendations) (tefferi2023polycythemiavera2024 pages 2-2, goratybor2024recommendationsofpolish pages 2-3). - Randomized trials (e.g., MAJIC-PV; Low-PV; REVIVE) (harrison2023ruxolitinibversusbest pages 1-2, barbui2023ropeginterferonversusstandard pages 1-2, kremyanskaya2024rusfertideahepcidin pages 1-2). - Real-world evidence / claims and EHR analyses (US claims; PV-NET; PV-AIM) (verstovsek2023realworldtreatmentsand pages 1-2, palandri2023predictorsofresponse pages 2-3).

2. Etiology

Primary causal factors

Somatic clonal hematopoiesis driven by activating JAK2 mutations is central: JAK2V617F is present in ~97% of cases; ~3% have other JAK2 mutations including exon 12 (tefferi2023polycythemiavera2024 pages 2-2). Constitutive JAK/STAT activation is repeatedly emphasized as core biology underlying PV manifestations and complications (harrison2023ruxolitinibversusbest pages 1-2).

Genetic risk factors / susceptibility loci (recent)

A 2023 genetic association study explicitly links iron regulation genetics (HFE) to PV diagnosis: - UK Biobank GWAS: 440 PV cases vs 403,351 controls; SNPs in HFE (known hemochromatosis variants) were “highly associated with PV diagnosis,” and FinnGen independently confirmed over-representation of homozygous HFE mutations in PV (bennett2023ironhomeostasisgoverns pages 1-7).

Environmental and clinical risk modifiers (evidence available)

• Cardiovascular risk factors (e.g., hypertension, dyslipidemia, obesity, smoking) are highlighted as relevant modifiers of overall thrombotic/cardiovascular risk in PV-focused reviews (verstovsek2023realworldtreatmentsand pages 1-2, silver2023polycythemiaveraaspects pages 1-3).
• Direct environmental exposures are not quantified in the captured evidence set.

Protective factors

• No definitive protective genetic variants are established in the retrieved evidence.
• Secondary prevention strategies (tight hematocrit control, antiplatelet therapy, cardiovascular risk modification) are repeatedly positioned as protective against thrombotic events (verstovsek2023realworldtreatmentsand pages 1-2, barbui2023ropeginterferonversusstandard pages 1-2).

Gene–environment / gene–physiology interaction (supported example)

PV phenotype appears to interact strongly with systemic iron biology: - Venesection-induced iron restriction is common, and hepcidin biology modifies disease severity in JAK2V617F PV mouse models (hepcidin upregulation alleviates; hepcidin loss worsens), implying that genetic/physiologic regulation of iron handling can modify PV expression (bennett2023ironhomeostasisgoverns pages 1-7).

3. Phenotypes

Core clinical phenotype spectrum (with frequencies where available)

From a large 2023 disease update, at/before presentation PV is associated with (examples below): - Palpable splenomegaly: ~36% (tefferi2023polycythemiavera2024 pages 2-2) - Prior thrombosis: ~25% (arterial 15–16%; venous 8–13%) (tefferi2023polycythemiavera2024 pages 2-2) - Major hemorrhage: ~4% (tefferi2023polycythemiavera2024 pages 2-2) - Symptoms/microvascular disturbances: headache, visual disturbances, erythromelalgia, pruritus, splenomegaly discomfort; presentations vary from asymptomatic to thrombotic/bleeding events (tefferi2023polycythemiavera2024 pages 2-2)

A separate expert review notes splenomegaly in a minority in a specific cohort (≈27% any; 6% >5 cm in one series), illustrating variability by cohort/definition (silver2023polycythemiaveraaspects pages 1-3).

Quality of life (QoL) impact (recent)

A 2024 review focused on low-risk PV reports substantial QoL impact: - ~80% report disease-related QoL impact; fatigue and sleep problems up to 79%; symptoms can include pruritus, pica, cognitive issues, falls, and poor exercise tolerance (visweshwar2024impactofphlebotomy pages 8-10). - Phlebotomy itself negatively affects QoL for many low-risk patients; ~25% reported negative QoL impact and up to 8% discontinued phlebotomy in one cited analysis (visweshwar2024impactofphlebotomy pages 8-10).

Suggested HPO terms (curated suggestions)

(Ontology mappings are suggested based on reported clinical features; the specific HPO IDs are not present in the evidence set and are therefore proposed as likely matches.) - Thrombosis (e.g., venous thrombosis; arterial thrombosis) - Pruritus - Splenomegaly - Headache - Erythromelalgia / microvascular disturbances - Leukocytosis, thrombocytosis, erythrocytosis / elevated hematocrit - Fatigue

4. Genetic / Molecular Information

Causal genes and mutation frequencies

• JAK2: driver mutation JAK2V617F in ~97%; other JAK2 mutations including exon 12 in ~3% (tefferi2023polycythemiavera2024 pages 2-2).

Additional (non-driver) mutations and prognostic genomics

Both a 2023 update and 2024 recommendations summarize frequent co-mutations: - Common: TET2 ~18%, ASXL1 ~15%, LNK ~3% (tefferi2023polycythemiavera2024 pages 7-8, goratybor2024recommendationsofpolish pages 2-3). - Adverse mutation sets (examples include SRSF2, IDH2, RUNX1, U2AF1) occur in a minority and are used in prognostic modeling (goratybor2024recommendationsofpolish pages 2-3, tefferi2023polycythemiavera2024 pages 7-8).

Somatic vs germline

• PV driver mutations and most co-mutations are treated as somatic clonal hematopoiesis features in the reviewed clinical literature (tefferi2023polycythemiavera2024 pages 2-2, harrison2023ruxolitinibversusbest pages 1-2).
• Germline susceptibility is suggested by the HFE-associated GWAS signal (bennett2023ironhomeostasisgoverns pages 1-7).

Functional consequences (high-level)

• JAK2 mutations lead to constitutive JAK-STAT activation with downstream inflammatory signaling and clinical complications (harrison2023ruxolitinibversusbest pages 1-2).

Epigenetics / chromosomal abnormalities

• Cytogenetic abnormalities are reported in ~15% (examples: trisomy 8/9; del13q; del20q), and marrow fibrosis is present in ~20% at diagnosis in one recommendation summary (goratybor2024recommendationsofpolish pages 2-3).

5. Environmental Information

Robust, specific environmental exposures (toxins/radiation) were not captured in the retrieved evidence. Cardiovascular comorbidity burden is consistently emphasized as clinically relevant to outcomes and management (verstovsek2023realworldtreatmentsand pages 1-2, silver2023polycythemiaveraaspects pages 1-3).

6. Mechanism / Pathophysiology

Central pathway: JAK–STAT–driven clonal myeloproliferation

• PV is mechanistically tied to JAK2-driven JAK/STAT signaling (tefferi2023polycythemiavera2024 pages 2-2, harrison2023ruxolitinibversusbest pages 1-2).

Thrombosis and “thrombo-inflammation” (recent mechanistic emphasis)

• Thrombosis is a dominant clinical problem; chronic inflammation and innate immune activation are repeatedly highlighted as contributors to vascular risk in PV/MPNs (verstovsek2023realworldtreatmentsand pages 1-2, barbui2026preservingthrombosisand pages 13-15).

Iron–hepcidin axis as a disease modifier (2023–2024 developments)

• 2023 GWAS and mouse genetic dissection link PV phenotype to hepcidin-regulated iron homeostasis: endogenous hepcidin upregulation alleviates erythroid disease; hepcidin ablation worsens it in JAK2V617F PV mouse models (bennett2023ironhomeostasisgoverns pages 1-7).
• Proposed mechanism includes inflammatory cytokine signaling via GP130-coupled receptors influencing hepcidin regulation in PV (bennett2023ironhomeostasisgoverns pages 1-7).

NETs and inflammatory biomarkers

• In PV, neutrophil activation and NET biology are implicated in thrombosis risk; a 2026 commentary frames NETs as repeatedly linked to thrombosis/atherosclerosis in MPNs and notes associations between leukocytosis/NLR and thrombosis (barbui2026preservingthrombosisand pages 13-15).

Suggested GO biological process terms (curated suggestions)

(Suggested based on described mechanisms; GO IDs not present in evidence set.) - JAK-STAT cascade - Cytokine-mediated signaling pathway - Regulation of iron ion homeostasis / hepcidin-mediated signaling - Blood coagulation / thrombus formation - Inflammatory response - Neutrophil activation and degranulation; NET formation

Suggested CL cell types (curated suggestions)

(Suggested based on described mechanisms; CL IDs not present in evidence set.) - Hematopoietic stem and progenitor cells - Erythroid progenitors - Megakaryocytes/platelets - Neutrophils - Endothelial cells

7. Anatomical Structures Affected

• Primary site: bone marrow (clonal myeloproliferation) (silver2023polycythemiaveraaspects pages 1-3).
• Secondary sites / complications: spleen (splenomegaly), arterial/venous vasculature (thrombosis, hemorrhage), and systemic involvement via inflammatory cytokines and cardiovascular risk (tefferi2023polycythemiavera2024 pages 2-2, verstovsek2023realworldtreatmentsand pages 1-2).

Suggested UBERON (curated): bone marrow, spleen, blood, vascular endothelium.

8. Temporal Development

• Typical median age at diagnosis ~61 years; ~10% diagnosed <40; sex distribution approximately equal (tefferi2023polycythemiavera2024 pages 2-2).
• PV is chronic with long survival measured in years to decades, but complicated by thrombosis and possible progression to post-PV myelofibrosis or AML (tefferi2023polycythemiavera2024 pages 2-2, verstovsek2023realworldtreatmentsand pages 1-2).

9. Inheritance and Population

Epidemiology (recent)

• Sweden (2000–2014): age-standardized PV incidence 1.48 per 100,000 person-years (tefferi2023polycythemiavera2024 pages 2-2).
• USA prevalence estimate 45–57 per 100,000 (verstovsek2023realworldtreatmentsand pages 1-2).

Demographics

• Median age ~61; ~10% <40; sex ~1:1 (tefferi2023polycythemiavera2024 pages 2-2).

Inheritance

PV is primarily a sporadic somatic clonal disorder (JAK2-driven), although germline susceptibility loci (e.g., HFE variants influencing iron regulation) may modify risk (tefferi2023polycythemiavera2024 pages 2-2, bennett2023ironhomeostasisgoverns pages 1-7).

10. Diagnostics

Standard diagnostic criteria (WHO 2022; ICC nuance)

A 2024 recommendation summarizing WHO 2022 states erythrocytosis thresholds: - Hb >16.5 g/dL (men), >16.0 g/dL (women) or Hct >49% (men), >48% (women) (goratybor2024recommendationsofpolish pages 2-3). - Bone marrow trephine showing panmyelosis is a WHO major criterion (goratybor2024recommendationsofpolish pages 2-3). - ICC allows omission of bone marrow in selected cases with very high Hb/Hct plus JAK2 mutation and low EPO (goratybor2024recommendationsofpolish pages 2-3).

Biomarkers and testing strategy (practical summary)

• JAK2 mutation testing (V617F; exon 12 if V617F-negative) is central (tefferi2023polycythemiavera2024 pages 2-2).
• Serum EPO: “low EPO” is emphasized in WHO/ICC frameworks (goratybor2024recommendationsofpolish pages 2-3).
• Consider expanded NGS to detect additional variants for prognosis (not mandatory universally) (tefferi2023polycythemiavera2024 pages 7-8).

Risk stratification used clinically

• Low-risk vs high-risk is commonly defined by age <60 and no thrombosis vs age ≥60 and/or prior thrombosis (verstovsek2023realworldtreatmentsand pages 1-2).

11. Outcome / Prognosis

Survival and major outcome drivers

• Real-world/guideline summaries report median survival ~12.4–20 years (range reflects cohorts/methods) (verstovsek2023realworldtreatmentsand pages 1-2).
• Thrombotic complications remain a key contributor to morbidity/mortality (verstovsek2023realworldtreatmentsand pages 1-2, goratybor2024recommendationsofpolish pages 2-3).

Prognostic modeling (clinical-genetic)

• MIPSS-PV: integrates clinical variables and adverse genetics; summarized median OS of 24 years (low), 13.1 years (intermediate), 3.2 years (high) (goratybor2024recommendationsofpolish pages 2-3, tefferi2023polycythemiavera2024 pages 7-8).
• In MAJIC-PV, ASXL1 mutations predicted adverse event-free survival (HR 3.02) (harrison2023ruxolitinibversusbest pages 1-2).

12. Treatment

Treatment goals (core concept)

Prevent thrombosis and manage symptom burden by maintaining hematocrit <45% and controlling blood counts and cardiovascular risk factors (verstovsek2023realworldtreatmentsand pages 1-2, barbui2023ropeginterferonversusstandard pages 1-2).

Standard therapies and real-world implementation

• Phlebotomy + low-dose aspirin is common initial therapy, especially in low-risk PV (verstovsek2023realworldtreatmentsand pages 1-2, barbui2023ropeginterferonversusstandard pages 1-2).
• Real-world US claims data show frequent underuse/undertitration in practice: among 28,306 PV patients, many remained on phlebotomy monotherapy and hematocrit control was often suboptimal (verstovsek2023realworldtreatmentsand pages 1-2).

Cytoreduction

Hydroxyurea (HU)

• PV-NET real-world cohort (n=563 on HU ≥12 months): 29.5% achieved ELN complete response; many patients were underdosed, and splenomegaly/symptoms often drove switching (palandri2023predictorsofresponse pages 2-3).

Interferon / ropeginterferon alfa-2b (2023–2024 evidence)

• Low-risk randomized phase 2 Low-PV trial: primary endpoint met in 81% with ropeginterferon vs 51% standard; maintained response at 24 months 83% vs 59%; improved symptom/spleen outcomes but discontinuations for adverse events occurred (barbui2023ropeginterferonversusstandard pages 1-2).

JAK inhibitor: ruxolitinib

• MAJIC-PV randomized phase II (HU-intolerant/resistant high-risk PV; n=180): complete response 43% vs 26% (ruxolitinib vs BAT), improved CR duration (HR 0.38), improved EFS (HR 0.58), and molecular response associated with improved PFS/EFS/OS; ASXL1 predicted worse EFS (harrison2023ruxolitinibversusbest pages 1-2).
• In previously untreated PV (RuxoBEAT futility analysis; n=28), ruxolitinib reduced hematocrit and phlebotomy needs and improved pruritus scores, with only grade 1–3 adverse events reported in this small cohort (koschmieder2023efficacyandsafety pages 1-2).

Emerging / novel therapies (2023–2024 priority)

Hepcidin mimetic: rusfertide

• REVIVE (NCT04057040), NEJM 2024: phlebotomies decreased from 8.7/year to 0.6/year during part 1; mean maximum hematocrit 44.5% vs 50.0% pre-treatment; randomized withdrawal response 60% vs 17% (rusfertide vs placebo; P=0.002); grade 3 adverse events 13%, no grade 4/5 events (kremyanskaya2024rusfertideahepcidin pages 1-2).
• Review synthesis emphasizes rusfertide as a candidate “chemical phlebotomy” approach and notes high rates of phlebotomy independence in phase 2 reporting; phase 3 is underway (handa2023hepcidinmimeticsin pages 4-6, handa2023hepcidinmimeticsin pages 13-15).

Suggested MAXO terms (curated suggestions)

(MAXO IDs not present in evidence set; suggested as likely actions) - Therapeutic phlebotomy - Antiplatelet therapy (aspirin) - Cytoreductive therapy (hydroxyurea; interferon) - Janus kinase inhibitor therapy (ruxolitinib) - Hepcidin mimetic therapy / iron restriction therapy (rusfertide)

13. Prevention

Primary prevention is not established (somatic clonal disorder), but secondary/tertiary prevention is central: - Maintain hematocrit <45% and manage cardiovascular risk factors to prevent thrombosis (verstovsek2023realworldtreatmentsand pages 1-2, goratybor2024recommendationsofpolish pages 2-3).

14. Other Species / Natural Disease

No naturally occurring PV analogue in non-human species was captured in the current evidence set.

15. Model Organisms

Mouse models (mechanistic utility)

• JAK2V617F PV mouse models are used to dissect phenotype modifiers; notably, hepcidin upregulation alleviates and hepcidin loss worsens erythroid disease in these models, supporting iron-homeostasis targeting (bennett2023ironhomeostasisgoverns pages 1-7).

Recent developments and real-world applications (2023–2024 highlights)

1. Hepcidin/iron axis as a therapeutic and etiologic lever: 2023 GWAS and mouse genetics support iron regulation as a modifier of PV phenotype (bennett2023ironhomeostasisgoverns pages 1-7).
2. Rusfertide (NEJM 2024) provides high-quality randomized withdrawal evidence for reducing phlebotomy dependence and maintaining hematocrit control with an acceptable safety profile (kremyanskaya2024rusfertideahepcidin pages 1-2).
3. Ruxolitinib (JCO 2023, MAJIC-PV) demonstrates superior complete response and event-free survival vs best available therapy in HU-intolerant/resistant PV; molecular response correlates with improved outcomes and ASXL1 predicts adverse EFS (harrison2023ruxolitinibversusbest pages 1-2).
4. Ropeginterferon alfa-2b (NEJM Evidence 2023) shows improved hematocrit-target maintenance and symptom/spleen endpoints in low-risk PV compared to phlebotomy-based standard approaches (barbui2023ropeginterferonversusstandard pages 1-2).
5. Real-world implementation gaps: US claims data show many patients initiate and remain on phlebotomy monotherapy and frequently have hematocrit >50%, with 16% experiencing thrombotic events after treatment initiation (verstovsek2023realworldtreatmentsand pages 1-2).

Summary evidence table

The following table consolidates key identifiers, statistics, and major trial outcomes used throughout this report.

Table: This table compiles high-yield quantitative findings and identifiers for polycythemia vera across epidemiology, molecular features, diagnosis, prognosis, and treatment studies. It is useful as a compact evidence map for rapid reference and knowledge-base curation.

Evidence limitations (important for knowledge-base ingestion)

• PMID requirement: The retrieved evidence snippets did not reliably include PMIDs; therefore, citations are provided using the system’s context IDs linked to DOI/journal sources. Where PMIDs are required, the cited DOI URLs can be used to resolve PubMed records.
• Ontology IDs (MONDO/OMIM/Orphanet/MeSH/ICD): Not present in the extracted text evidence and therefore not asserted.
• HPO/GO/CL/MAXO IDs: Suggested conceptually based on phenotype/mechanism descriptions but not sourced as explicit IDs from retrieved ontology resources.

References

1. (tefferi2023polycythemiavera2024 pages 2-2): Ayalew Tefferi and Tiziano Barbui. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 98:1465-1487, Jun 2023. URL: https://doi.org/10.1002/ajh.27002, doi:10.1002/ajh.27002. This article has 254 citations and is from a domain leading peer-reviewed journal.

2. (silver2023polycythemiaveraaspects pages 1-3): Richard T Silver and Ghaith Abu-Zeinah. Polycythemia vera: aspects of its current diagnosis and initial treatment. Expert Review of Hematology, 16:253-266, Apr 2023. URL: https://doi.org/10.1080/17474086.2023.2198698, doi:10.1080/17474086.2023.2198698. This article has 8 citations and is from a peer-reviewed journal.

3. (goratybor2024recommendationsofpolish pages 2-3): Joanna Góra-Tybor, Tomasz Sacha, Maria Bieniaszewska, Marta Sobas, Krzysztof Lewandowski, Patryk Sobieralski, Olga Chyrko, and Aleksandra Gołos. Recommendations of polish adult leukemia group concerning diagnostics and treatment of polycythemia vera. Acta Haematologica Polonica, 55:289-305, Dec 2024. URL: https://doi.org/10.5603/ahp.102458, doi:10.5603/ahp.102458. This article has 5 citations.

4. (harrison2023ruxolitinibversusbest pages 1-2): Claire N. Harrison, Jyoti Nangalia, Rebecca Boucher, Aimee Jackson, Christina Yap, Jennifer O'Sullivan, Sonia Fox, Isaak Ailts, Amylou C. Dueck, Holly L. Geyer, Ruben A. Mesa, William G. Dunn, Eugene Nadezhdin, Natalia Curto-Garcia, Anna Green, Bridget Wilkins, Jason Coppell, John Laurie, Mamta Garg, Joanne Ewing, Steven Knapper, Josephine Crowe, Frederick Chen, Ioannis Koutsavlis, Anna Godfrey, Siamak Arami, Mark Drummond, Jennifer Byrne, Fiona Clark, Carolyn Mead-Harvey, Elizabeth Joanna Baxter, Mary Frances McMullin, and Adam J. Mead. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. Journal of Clinical Oncology, 41:3534-3544, Jul 2023. URL: https://doi.org/10.1200/jco.22.01935, doi:10.1200/jco.22.01935. This article has 162 citations and is from a highest quality peer-reviewed journal.

5. (barbui2023ropeginterferonversusstandard pages 1-2): Tiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, Alessandra Carobbio, Arianna Ghirardi, Greta Carioli, Arianna Masciulli, Elena Rossi, Fabio Ciceri, Massimiliano Bonifacio, Alessandra Iurlo, Francesca Palandri, Giulia Benevolo, Fabrizio Pane, Alessandra Ricco, Giuseppe Carli, Marianna Caramella, Davide Rapezzi, Caterina Musolino, Sergio Siragusa, Elisa Rumi, Andrea Patriarca, Nicola Cascavilla, Barbara Mora, Emma Cacciola, Carmela Mannarelli, Giuseppe Gaetano Loscocco, Paola Guglielmelli, Francesca Gesullo, Silvia Betti, Francesca Lunghi, Luigi Scaffidi, Cristina Bucelli, Nicola Vianelli, Marta Bellini, Maria Chiara Finazzi, Gianni Tognoni, and Alessandro Rambaldi. Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. NEJM Evidence, May 2023. URL: https://doi.org/10.1056/evidoa2200335, doi:10.1056/evidoa2200335. This article has 62 citations and is from a peer-reviewed journal.

6. (kremyanskaya2024rusfertideahepcidin pages 1-2): Marina Kremyanskaya, Andrew T. Kuykendall, Naveen Pemmaraju, Ellen K. Ritchie, Jason Gotlib, Aaron Gerds, Jeanne Palmer, Kristen Pettit, Uttam K. Nath, Abdulraheem Yacoub, Arturo Molina, Samuel R. Saks, Nishit B. Modi, Frank H. Valone, Sarita Khanna, Suneel Gupta, Srdan Verstovsek, Yelena Z. Ginzburg, and Ronald Hoffman. Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. The New England journal of medicine, 390 8:723-735, Feb 2024. URL: https://doi.org/10.1056/nejmoa2308809, doi:10.1056/nejmoa2308809. This article has 56 citations and is from a highest quality peer-reviewed journal.

7. (verstovsek2023realworldtreatmentsand pages 1-2): Srdan Verstovsek, Naveen Pemmaraju, Nancy L. Reaven, Susan E. Funk, Tracy Woody, Frank Valone, and Suneel Gupta. Real-world treatments and thrombotic events in polycythemia vera patients in the usa. Annals of Hematology, 102:571-581, Jan 2023. URL: https://doi.org/10.1007/s00277-023-05089-6, doi:10.1007/s00277-023-05089-6. This article has 28 citations and is from a peer-reviewed journal.

8. (palandri2023predictorsofresponse pages 2-3): Francesca Palandri, Elena Rossi, Giuseppe Auteri, Massimo Breccia, Simona Paglia, Giulia Benevolo, Elena M. Elli, Francesco Cavazzini, Gianni Binotto, Alessia Tieghi, Mario Tiribelli, Florian H. Heidel, Massimiliano Bonifacio, Novella Pugliese, Giovanni Caocci, Monica Crugnola, Francesco Mendicino, Alessandra D'Addio, Simona Tomassetti, Bruno Martino, Nicola Polverelli, Sara Ceglie, Camilla Mazzoni, Rikard Mullai, Alessia Ripamonti, Bruno Garibaldi, Fabrizio Pane, Antonio Cuneo, Mauro Krampera, Gianpietro Semenzato, Roberto M. Lemoli, Nicola Vianelli, Giuseppe A. Palumbo, Alessandro Andriani, Michele Cavo, Roberto Latagliata, and Valerio De Stefano. Predictors of response to hydroxyurea and switch to ruxolitinib in hu-resistant polycythaemia vera patients: a real-world pv-net study. Cancers, 15:3706, Jul 2023. URL: https://doi.org/10.3390/cancers15143706, doi:10.3390/cancers15143706. This article has 13 citations.

9. (bennett2023ironhomeostasisgoverns pages 1-7): Cavan Bennett, Victoria E Jackson, Anne Pettikiriarachchi, Thomas Hayman, Ute Schaeper, Gemma Moir-Meyer, Katherine Fielding, Ricardo Ataide, Danielle Clucas, Andrew Baldi, Alexandra L Garnham, Connie SN Li-Wai-Suen, Stephen J Loughran, E Joanna Baxter, Anthony R Green, Warren S Alexander, Melanie Bahlo, Kate Burbury, Ashley P Ng, and Sant-Rayn Pasricha. Iron homeostasis governs erythroid phenotype in polycythemia vera. JournalArticle, Mar 2023. URL: https://doi.org/10.17863/cam.95022, doi:10.17863/cam.95022. This article has 17 citations.

10. (visweshwar2024impactofphlebotomy pages 8-10): Nathan Visweshwar, Bradley Fletcher, Michael Jaglal, Damian A. Laber, Ankita Patel, Jennifer Eatrides, Geetha Rajasekharan Rathnakumar, Keshav Visweswaran Iyer, Irmel Ayala, and Arumugam Manoharan. Impact of phlebotomy on quality of life in low-risk polycythemia vera. Journal of Clinical Medicine, 13:4952, Aug 2024. URL: https://doi.org/10.3390/jcm13164952, doi:10.3390/jcm13164952. This article has 5 citations.

11. (tefferi2023polycythemiavera2024 pages 7-8): Ayalew Tefferi and Tiziano Barbui. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 98:1465-1487, Jun 2023. URL: https://doi.org/10.1002/ajh.27002, doi:10.1002/ajh.27002. This article has 254 citations and is from a domain leading peer-reviewed journal.

12. (barbui2026preservingthrombosisand pages 13-15): Tiziano Barbui, Arianna Ghirardi, Annalisa Condorelli, and Marta Sobas. Preserving thrombosis and life years in polycythemia vera: start by reading the biology of the disease. Haematologica, Feb 2026. URL: https://doi.org/10.3324/haematol.2025.300028, doi:10.3324/haematol.2025.300028. This article has 0 citations.

13. (koschmieder2023efficacyandsafety pages 1-2): Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Florian H. Heidel, Andreas Hochhaus, Philippe Schafhausen, Martin Griesshammer, Denise Wolleschak, Uwe Platzbecker, Konstanze Döhner, Philipp J. Jost, Stefani Parmentier, Markus Schaich, Nikolas von Bubnoff, Frank Stegelmann, Angela Maurer, Martina Crysandt, Deniz Gezer, Maike Kortmann, Jeremy Franklin, Julia Frank, Martin Hellmich, and Tim H. Brümmendorf. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the ruxobeat clinical trial of the gsg-mpn study group. Annals of Hematology, 102:349-358, Dec 2023. URL: https://doi.org/10.1007/s00277-022-05080-7, doi:10.1007/s00277-022-05080-7. This article has 11 citations and is from a peer-reviewed journal.

14. (handa2023hepcidinmimeticsin pages 4-6): Shivani Handa, Yelena Ginzburg, Ronald Hoffman, and Marina Kremyanskaya. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. Current Opinion in Hematology, 30:45-52, Dec 2023. URL: https://doi.org/10.1097/moh.0000000000000747, doi:10.1097/moh.0000000000000747. This article has 29 citations and is from a peer-reviewed journal.

15. (handa2023hepcidinmimeticsin pages 13-15): Shivani Handa, Yelena Ginzburg, Ronald Hoffman, and Marina Kremyanskaya. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis. Current Opinion in Hematology, 30:45-52, Dec 2023. URL: https://doi.org/10.1097/moh.0000000000000747, doi:10.1097/moh.0000000000000747. This article has 29 citations and is from a peer-reviewed journal.

16. (tefferi2023polycythemiavera2024 pages 13-13): Ayalew Tefferi and Tiziano Barbui. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management. American Journal of Hematology, 98:1465-1487, Jun 2023. URL: https://doi.org/10.1002/ajh.27002, doi:10.1002/ajh.27002. This article has 254 citations and is from a domain leading peer-reviewed journal.